311 related articles for article (PubMed ID: 28860080)
1. Rituximab desensitization in three patients with severe rituximab allergy.
Öztürk E; Özyiğit LP; Öztürk AB; Akay MO; Çetiner M; Ferhanoğlu B
Curr Probl Cancer; 2017; 41(5):349-354. PubMed ID: 28860080
[TBL] [Abstract][Full Text] [Related]
2. Rituximab Hypersensitivity: Evaluation, Desensitization, and Potential Mechanisms.
Wong JT; Long A
J Allergy Clin Immunol Pract; 2017; 5(6):1564-1571. PubMed ID: 29122155
[TBL] [Abstract][Full Text] [Related]
3. Rapid Drug Desensitization With Rituximab in 24 Cases: A Single-Center Experience.
Görgülü B; Seval GC; Kendirlinan R; Toprak SK; Özcan M; Bavbek S
J Investig Allergol Clin Immunol; 2019; 29(6):468-470. PubMed ID: 31530515
[No Abstract] [Full Text] [Related]
4. Hypersensitivity reactions to rituximab: 53 successful desensitizations in 7 patients with severe, near-fatal reactions.
Lebel E; Ben-Yehuda D; Bohbot E; Dranitzki Z; Shalit M; Tal Y
J Allergy Clin Immunol Pract; 2016; 4(5):1000-2. PubMed ID: 27329468
[No Abstract] [Full Text] [Related]
5. Desensitization to rituximab in a multidisciplinary setting.
Amorós-Reboredo P; Sánchez-López J; Bastida-Fernández C; do Pazo-Oubiña F; Borràs-Maixenchs N; Giné E; Valero A; Creus-Baró N
Int J Clin Pharm; 2015 Oct; 37(5):744-8. PubMed ID: 25999014
[TBL] [Abstract][Full Text] [Related]
6. Presentation and management of the delayed type of hypersensitivity reaction with bendamustine.
Shikdar S; Totton D; Turco T; Rachshtut M
Anticancer Drugs; 2018 Sep; 29(8):814-816. PubMed ID: 29877929
[TBL] [Abstract][Full Text] [Related]
7. Rituximab desensitization in pediatric acute lymphoblastic leukemia with severe anaphylaxis.
V Villarreal-González R; E de Lira-Quezada C; N González-Díaz S; L Carrasco-Díaz L; González-Llano O
J Oncol Pharm Pract; 2021 Apr; 27(3):747-750. PubMed ID: 32787558
[TBL] [Abstract][Full Text] [Related]
8. Rapid desensitization of hypersensitivity reactions to chemotherapy agents.
Castells M
Curr Drug Saf; 2006 Aug; 1(3):243-51. PubMed ID: 18690934
[TBL] [Abstract][Full Text] [Related]
9. Incidence of interstitial pneumonitis in non-Hodgkin's lymphoma patients receiving immunochemotherapy with pegylated liposomal doxorubicin and rituximab.
Zhou T; Shen Q; Peng H; Chao T; Zhang L; Huang L; Yang K; Thapa S; Yu S; Jiang Y
Ann Hematol; 2018 Jan; 97(1):141-147. PubMed ID: 29086009
[TBL] [Abstract][Full Text] [Related]
10. Rapid desensitization to brentuximab vedotin after severe anaphylaxis in the treatment of refractory Hodgkin's lymphoma.
V Villarreal-Gonzalez R; N Gonzalez-Diaz S; E de Lira-Quezada C; Gómez-Almaguer D; Gómez-De León A; Acuña-Ortega N
J Oncol Pharm Pract; 2021 Mar; 27(2):505-508. PubMed ID: 32686619
[TBL] [Abstract][Full Text] [Related]
11. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature.
Grisariu S; Vaxman I; Gatt M; Elias S; Avni B; Arad A; Pasvolsky O; Raanani P; Paltiel O
Hematol Oncol; 2017 Dec; 35(4):591-598. PubMed ID: 27734521
[TBL] [Abstract][Full Text] [Related]
12. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment.
Brennan PJ; Rodriguez Bouza T; Hsu FI; Sloane DE; Castells MC
J Allergy Clin Immunol; 2009 Dec; 124(6):1259-66. PubMed ID: 19910036
[TBL] [Abstract][Full Text] [Related]
13. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases.
Castells MC; Tennant NM; Sloane DE; Hsu FI; Barrett NA; Hong DI; Laidlaw TM; Legere HJ; Nallamshetty SN; Palis RI; Rao JJ; Berlin ST; Campos SM; Matulonis UA
J Allergy Clin Immunol; 2008 Sep; 122(3):574-80. PubMed ID: 18502492
[TBL] [Abstract][Full Text] [Related]
14. [Castleman's disease: Rapid desensitization for hypersensitivity reaction to rituximab].
Boin C; Lambert S; Thomann P; Aujoulat O; Kieffer P
Rev Med Interne; 2016 Jun; 37(6):433-6. PubMed ID: 26415921
[TBL] [Abstract][Full Text] [Related]
15. Outcome of 490 Desensitizations to Chemotherapy Drugs with a Rapid One-Solution Protocol.
Pérez-Rodríguez E; Martínez-Tadeo JA; Pérez-Rodríguez N; Hernández-Santana G; Callero-Viera A; Rodríguez-Plata E; García-Robaina JC
J Allergy Clin Immunol Pract; 2018; 6(5):1621-1627.e6. PubMed ID: 29361511
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.
D'Arena G; Simeon V; Laurenti L; Cimminiello M; Innocenti I; Gilio M; Padula A; Vigliotti ML; De Lorenzo S; Loseto G; Passarelli A; Di Minno MND; Tucci M; De Feo V; D'Auria F; Silvestris F; Di Minno G; Musto P
Leuk Lymphoma; 2017 Nov; 58(11):2633-2641. PubMed ID: 28367662
[TBL] [Abstract][Full Text] [Related]
17. Drug desensitization in allergic children.
Caimmi S; Caffarelli C; Saretta F; Liotti L; Crisafulli G; Cardinale F; Bottau P; Mori F; Franceschini F; Bernardini R; Marseglia GL
Acta Biomed; 2019 Jan; 90(3-S):20-29. PubMed ID: 30830058
[TBL] [Abstract][Full Text] [Related]
18. Desensitization protocol for rituximab-induced serum sickness.
Fajt ML; Petrov AA
Curr Drug Saf; 2014; 9(3):240-2. PubMed ID: 24861993
[TBL] [Abstract][Full Text] [Related]
19. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
20. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma.
Sacchi S; Federico M; Vitolo U; Boccomini C; Vallisa D; Baldini L; Petrini M; Rupoli S; Di Raimondo F; Merli F; Liso V; Tabilio A; Saglio G; Vinci G; Brugiatelli M; Dastoli G;
Haematologica; 2001 Sep; 86(9):951-8. PubMed ID: 11532623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
